Pharmaxis Cancer Drug Progressing in Clinic
Release Date: 24/10/2019 8:27am
Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced that following positive clinical Phase 1A study results, it has begun dosing healthy subjects in the second stage of its study of an oral anti-fibrotic Lysyl Oxidase (LOX) inhibitor. This drug is being targeted to treat cancers including myelofibrosis and pancreatic cancer.
Categories: News and Media